Anebulo Pharmaceuticals, Inc.
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
ANEB | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- C/O ANEBULO PHARMACEUTICALS, INC., 78734 LAKEWAY
- Website:
- https://www.anebulo.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for acute cannabinoid intoxication (ACI). Addressing the growing unmet medical need for an antidote to cannabis poisoning, which has increased with widespread legalization, the company's lead investigational candidate is ANEB-001. ANEB-001 is a potent cannabinoid antagonist designed to rapidly reverse the psychoactive and physiological effects of cannabinoid overdose. The product is in clinical development to serve as a potential treatment for patients, including children, who present in emergency rooms with unintentional cannabis poisoning.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Anebulo Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Anebulo Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Anebulo Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
